Plus Therapeutics

04/08/2026

announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas.

Notably, the granted orphan designation for malignant glioma more broadly than originally requested, encompassing pediatric ependymoma.

Full press release here: bit.ly/4e4A82E

04/07/2026

announces that the American Medical Association has approved a new, Proprietary Laboratory Analyses Current Procedural Terminology code for CNSide Diagnostics' Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test.

The dedicated billing code, 0640U, effective July 1, 2026, establishes a unique reimbursement identifier for the CSF TCE test, supporting payer claims processing and facilitating broader clinical adoptions as continues the U.S. commercial launch of its CNS metastases diagnostic platform.

Full press release here: bit.ly/4myP1wB

04/02/2026

announces a new payer coverage agreement with Highmark Blue Cross Blue Shield, effective April 1, 2026, providing reimbursement for CNSide Diagnostics' Cerebrospinal Fluid Tumor Cell Enumeration assay for patients with metastatic central nervous system cancers.

joins a growing list of national and regional payers, including UnitedHealthcare and Humana, that provide coverage for ® .

Full press release here: https://bit.ly/3PLOMBV

04/01/2026

issues a proxy letter to stockholders, including an invitation to attend the 2026 Annual Meeting. This meeting will be held on May 14, 2026, commencing at 9:00 a.m. ET, and will be a completely virtual meeting of stockholders.

Read more: bit.ly/4tiC4ZH

Nasdaq:

03/30/2026

Numbers matter in (LM) care.

The CNSide Diagnostics CSF Assay Platform delivers actionable insights from a single cerebrospinal fluid sample. This provides data that can empower clinicians to confirm or rule out LM, and offers the opportunity to monitor disease progression and treatment response through serial testing.

With studies that show CNSide’s enhanced sensitivity vs. CSF cytology and its ability to inform clinical decisions in over 90% of cases, ® is helping clinicians move from uncertainty to clarity.

Learn more: https://cnside-dx.com/cnside-csf-assay/

03/26/2026

announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors.

Mr. Andrews currently is an experienced leader in the Diagnostics and Molecular Diagnostics industry with over 35 years leading various sized organizations from divisions of large global entities such as Abbott Diagnostics, Roche Molecular Diagnostics and LifeTechnologies / Thermo Fisher to public CEO roles in successful start-up organizations like Clarient Inc. (NASDAQ: CLRT) and Oncocyte Inc. (NASDAQ: OCX).

Full press release here: bit.ly/3NuNbjb

CNSide Diagnostics

03/24/2026

President & CEO, Marc Hedrick, MD, joined Ben Comer on Business of Biotech to discuss the urgent need for innovation in cancers.

Dr. Hedrick also explained the science behind , including why Rhenium-186 was selected as the radioisotope, and shared insights from CNSide Diagnostics on advancing early detection and treatment.

Tune in to hear how Plus Therapeutics is working to address the critical unmet needs in CNS cancer: https://bit.ly/4lKAMnM

03/23/2026

The CNSide Diagnostics team will be at the American Association for Cancer Research’s Special Conference in Cancer Research: Brain Cancer, starting today in Philadelphia.

Meet with the team to discuss more about the CSF Assay, designed to deliver actionable insights from a single cerebrospinal fluid sample to provide more complete data to guide decisions for your patients with .



https://www.facebook.com/cnsidediagnostics/posts/pfbid0wyaWsyP44PJUeN7favC6h4BYrEFyBEjBcRnHHa78QguNrs31YNP6sMbEUoJUMiAgl

CNSide Diagnostics is looking forward to attending the AACR Special Conference in Cancer Research: Brain Cancer, taking place March 23–25 in Philadelphia.

This meeting, organized by the American Association for Cancer Research, convenes leading clinicians and researchers to discuss advances in the biology and treatment of brain tumors, including emerging insights into gliomas, neuro-immuno-oncology, cellular therapies, and CNS metastases.

Our team looks forward to engaging with the neuro-oncology community and discussing how the CNSide Cerebrospinal Fluid Assay Platform is working to provide additional diagnostic insights for patients with suspected Leptomeningeal Metastases.

If you are attending, we welcome the opportunity to connect and discuss the evolving role of CSF-based diagnostics in neuro-oncology.

Learn more about the meeting:
https://hubs.la/Q046NG8q0
Contact us to learn more or to meet us at the event: https://hubs.la/Q046NPPP0

03/19/2026

announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using CNSide Diagnostics' cerebrospinal fluid (CSF) assay.

The findings support the potential clinical and economic value of as the Company advances commercialization of the assay in the United States.

The data will be presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research’s 2026 Annual Meeting, the leading global scientific conference focused on health
economics and outcomes research, bringing together researchers, healthcare.

Full press release here: https://bit.ly/4rII114

More about CNSide: https://bit.ly/4teT57l

03/17/2026

Precision matters in cancer treatment.

is building a platform designed to deliver high-dose radiation directly to tumors, aiming to maximize tumor impact while sparing healthy tissue.

President & CEO, Marc Hedrick, recently talked with Karen Jagoda about our precision radiotherapeutic development on the Empowered Patient podcast here: https://bit.ly/3NE4uxY

Empowered Patient Radio

03/13/2026

For patients with suspected , time matters.

The CNSide Diagnostics' test delivers highly sensitive analysis of tumor cells in cerebrospinal fluid, providing clinicians with comprehensive data to detect disease, characterize tumor biology, and monitor treatment effects.

Learn what physicians are saying about ®: cnside-dx.com

03/09/2026

International Women’s Day was yesterday and March is Women’s History Month.

Our team honors the women advancing science, medicine, and innovation to push the boundaries of cancer treatment to bring hope to patients and families worldwide.